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Abstract
Background: The use of gene expression profiling in both clinical and laboratory settings would be
enhanced by better characterization of variance due to individual, environmental, and technical factors.
Meta-analysis of microarray data from untreated or vehicle-treated animals within the control arm of
toxicogenomics studies could yield useful information on baseline fluctuations in gene expression, although
control animal data has not been available on a scale and in a form best served for data-mining.
Results: A dataset of control animal microarray expression data was assembled by a working group of
the Health and Environmental Sciences Institute's Technical Committee on the Application of Genomics
in Mechanism Based Risk Assessment in order to provide a public resource for assessments of variability
in baseline gene expression. Data from over 500 Affymetrix microarrays from control rat liver and kidney
were collected from 16 different institutions. Thirty-five biological and technical factors were obtained for
each animal, describing a wide range of study characteristics, and a subset were evaluated in detail for their
contribution to total variability using multivariate statistical and graphical techniques.
Conclusion: The study factors that emerged as key sources of variability included gender, organ section,
strain, and fasting state. These and other study factors were identified as key descriptors that should be
included in the minimal information about a toxicogenomics study needed for interpretation of results by
an independent source. Genes that are the most and least variable, gender-selective, or altered by fasting
were also identified and functionally categorized. Better characterization of gene expression variability in
control animals will aid in the design of toxicogenomics studies and in the interpretation of their results.
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Background
Animal models are routinely used to assess the risk of
exposure to drugs and chemicals for the human popula-
tion. Whole genome sequencing and microarray technol-
ogy have added new tools that can be integrated into
traditional toxicity testing strategies for enhanced predic-
tive and mechanistic insights. Variations in study design
are typical for toxicogenomics studies, but their impact on
gene expression in control animals has not been well char-
acterized. Several studies are available that have examined
factors contributing to variation in gene expression in
human peripheral blood [1,2]. A limited number of stud-
ies have been published on individual animal variability
[3] and the effect of selected study conditions [4-6] on
baseline gene expression patterns in the control arm of
toxicity studies in rats.
Databases of historical background levels have utility for
toxicologic risk assessment. For example, the Registry of
Industrial Toxicology Animal database of historical tumor
data is used to interpret tumor incidence rates in long-
term rodent carcinogenicity bioassays [7]. In September
2004, the ILSI Health and Environmental Sciences Insti-
tute (HESI) Technical Committee on the Application of
Genomics in Mechanism Based Risk Assessment initiated
a plan to populate a publicly accessible dataset of control
animal microarray data to serve as a resource for analysis
of baseline fluctuations in gene expression due to biolog-
ical or technical factors. Datasets from control animals
within toxicogenomics study arms were solicited from
HESI participants in the US and Europe. The dataset was
limited to rat liver and kidney samples run on Affymetrix
arrays in order to harmonize the appropriate data format
and content for the dataset, and the feasibility of compar-
ing signal data across multiple sites and conditions. Infor-
mation was collected on common variables in toxicity
studies (e.g., dosing regimen) and other known con-
founding factors that can affect sensitivity to chemicals in
toxicity studies (strain, supplier, gender, diet, and age) [8].
In this paper, the collected control animal microarray data
is analyzed for the contribution of different study factors
to baseline variability in gene expression. Genes were
identified which had the most and least inherent variabil-
ity, were gender-selective, or altered by fasting.
Results
Dataset description
To populate a dataset of baseline gene expression, volun-
tary contributions of microarray data from the control
arms of toxicogenomics studies of liver and kidney were
requested from HESI member institutions. A survey form
was developed and sent to contributors requesting meta-
data about the study including information on subject
characteristics and husbandry, euthanasia methods, spec-
imen preparation and preservation protocols, RNA prepa-
ration and labeling, and microarray hybridization (Table
1). On receipt of the data from contributors, terms were
harmonized and entered into binned ranges where
needed (e.g., age), and anonymized as to contributing
institution.
Signal data from a total of 536 microarrays were received
from 16 institutions and 48 in-life studies. Each study
contains a unique combination of treatments and han-
dling conditions. The data was collected on 3 Affymetrix
rat expression array types (RGU34A (n = 192), RAE230A
(n = 213), and RAE230 2.0 (n = 131)) for two tissues, liver
(n = 396) and kidney (n = 140). For further analysis, the
data was partitioned into 6 tissue-array sets. The dataset
also included 3 rat strains (Sprague-Dawley (n = 302),
Wistar (n = 210), and F344/N (n = 24)) and both males
(n = 436) and females (n = 100). A list of the 38 study fac-
tors requested with the data submissions is included in
Table 1. Details on the distribution in the collected data of
22 of the 38 study factors are contained in Additional file
1. Complete information was not received for every study
factor for all contributed microarray data files.
Fifty-three data files were excluded from further analysis
because they were associated with factors known to
impair data comparability (high photomultiplier tube set-
ting on scanner, quality metric outlier) or that were iden-
tified to be duplicate submissions. The remaining 483 sets
of array data were processed using Robust Multi-array
Average (RMA) separately for each of the 3 array types in
the dataset.
Variability analysis
To statistically assess prominent sources of variability in
the data, we used several multivariate techniques, applied
separately on each of the six tissue-array data subsets for
15 fully entered study factors and 2 study factors with par-
tial entries (listed in Table 2). Within each subset, the
genes were individually mean-centered, that is, the mean
of the log2 intensity values for each gene was subtracted
from each of its values, and principal components were
computed. The first two components were plotted using
different colors and markers to label the various factors in
an ad hoc fashion. This approach enabled identification
of several factors associated directly with clusters of prin-
cipal component scores. For example, organ section was
observed to be a prominent source of variability in the
kidney RAE230 2.0 dataset (Figure 1A). In contrast, anal-
ysis of the liver RAE230 2.0 dataset was less straightfor-
ward because of confounding between sites, diet, strain,
and fasting (Figure 1B). Principal component analyses of
other tissue-array sets are available in Additional file 2.
The principal component scores for these analyses are
available at both the Chemical Effects in Biological Sys-BMC Genomics 2008, 9:285 http://www.biomedcentral.com/1471-2164/9/285
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tems Biomedical Investigation Database (CEBS-BID) [9]
and ArrayExpress at EBI [10].
To more formally assess contributions to variability,
Hotelling-Lawley (HL) and Variance Components (VC)
scores were computed for each of the 17 study factors in
each six tissue-array set. HL statistics provide individual
factor scores for the degree of variability explained, as
compared to a maximal model that includes every distinct
factor combination for that data subset. The significance
of an individual effect according to HL does not necessar-
ily indicate that a particular effect is a true source of varia-
bility, because it may be confounded with other effects,
but it does indicate that at least one source is likely
present. Variance Component (VC) scores are different
from HL in that they sum to one and provide a simultane-
ous partitioning of total variability. VC scores are subject
to a degree of indeterminability when there is complete
confounding between two or more factors. In this case,
the proportion of variability shared amongst confounded
factors is assigned to factors in a way that is dependent on
their order in the model and the specific REML algorithm
employed. The total fraction of variability assigned to
those factors is preserved, so where only one of the con-
founded factors is a true source of variability, the assigned
VC score to it will tend to be biased downwards.
The results of the multivariate variability analyses when
viewed in summary across the six tissue-array sets indicate
that gender, fasting, strain, and organ section were the
most reproducibly prominent biological factors associ-
ated with gene expression variance between control ani-
mals in this dataset (Table 2). While lab (or institution)
was a clearly observable source of variance, it was always
confounded by a unique combination of study factors
used within each laboratory's in-life studies and possible
contributions to variance from technical factors which
cannot be discerned in this analysis. Since the collected
data are observational (that is, not from a single designed
experiment), extreme care must be taken in interpreting
large scores because many factors are completely or par-
tially confounded with others. In addition, the meaning
of a particular factor can change from subset to subset,
depending on its observed levels. Tabular displays of fac-
tor combinations alongside the HL and VC statistics are
available in Additional file 3 to aid in discerning con-
founding relationships.
To further explore attributable variability, we performed a
discriminant analysis on the following factors: gender,
diet, strain, fasted, and coded study (nested within lab).
The first ten principal components were used as predictors
for this analysis. The resulting first two canonical scores
for the three liver data sets are plotted and labeled in Fig-
ure 2. The figure reveals very clear clusters of points assign-
able to distinct levels of the different factors; however, it is
important to realize that a confounded factor may in fact
be the true cause for the clustering. Table 3 shows factors
observed to be confounded with those analyzed in Figure
2. The confounding relationships were determined by fit-
ting a partition tree model to each factor in Figure 2, using
the other 16 factors as predictors. Additional files 4 and 5
contain a similar figure and table for kidney, and Addi-
tional file 3 details full interrelationships amongst factor
levels.
Table 1: Study factors collected with control animal microarray 
data
Category Study Factor Query
Study Organism name
Animal strain
Sex
Study number
Institution
Subject characteristics Individual animal identifier
Animal supplier
Animal age at sacrifice
Total body weight at sacrifice
Time of day at sacrifice (AM or PM)
Husbandry Diet name and source
Diet availability
Number of animal in a cage
Number of hours of light per day
Was food withheld prior to sacrifice?
Fasted > 12 hr?
Blood collection during in life study?
If yes, time of collection relative to sacrifice
Specimen Organ Sampled
Organ section sampled
Organ preservation method
Organ weight at sacrifice
Euthanasia Sacrifice method
Exsanguinated?
Anesthetic used
Treatment Vehicle
Route of vehicle administration
Frequency of dosing
Duration of dosing
Dose volume
Time between dosing and sacrifice
Microarray experiment RNA extraction protocol
Quality parameters for RNA
Sample preparation protocol
Rounds of amplification
Amount of RNA on array
Array type used
Scanner modelBMC Genomics 2008, 9:285 http://www.biomedcentral.com/1471-2164/9/285
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Individual gene variance analysis
Variance in gene expression between individuals in con-
trol groups may be attributed to differences in environ-
mental factors, genetic background, and measurement
reliability. Gene variance that is consistently observed
among control animals but cannot be readily attributed to
any identified study factor can adversely affect the reliabil-
ity and reproducibility of toxicogenomics data. To identify
probes in this HESI project that had the highest and most
consistent baseline variance not attributable to any
known study factors, expressed probes in each tissue-array
set with the highest baseline variance (top 2%) were inter-
Table 2: Summary of study factors with significant Hotelling-Lawley (H) and Variance Components (V) scores in each tissue-array set
Liver RAE230A Liver RAE230 2.0 Liver RGU34A Kidney RAE230A Kidney RAE230 2.0 Kidney RGU34A
Gender Ha Vb -c VH  V V d
Fasted V H V V -
Strain V H - H V
Organ Section H - HV -
Fixation V - - H V
RNA Amount V H - H
Lab H H H
Dose Duration H V H
Vehicle H H H
Sacrifice Method V H -
Diet H V -
Study(Lab) H
Route V -
Age H
Dose Frequency V - -
Scanner - V - -
Anesthetic -
aH: Large Hotelling-Lawley statistic (HLi > 35% of HLfull)
bV: Large Variance Components statistic (Vi > Verror)
c"-" Not tested (single factor level within tissue-array set)
dBlank: Small effect for both H and V
Principal components analysis of control kidney and liver data Figure 1
Principal components analysis of control kidney and liver data. Principal components were computed for normalized 
intensities from (A) kidney and (B) liver samples run on RAE230 2.0 arrays. The first two principal components are shown, 
which together explain about 80% and 53% of the total variation for kidney and liver, respectively. Each point in the plot repre-
sents an individual sample. (A) For kidney, organ section (indicated by color) appears to be the prominent explanatory factor. 
Lab is indicated by marker shape and gender is indicated by marker size. (B) Lab, diet, and fasting (indicated by color, shape, and 
size, respectively) are confounded in the liver dataset, and their respective levels are strongly associated with three distinct 
clusters. The sources and numbers of the 3 rat chows used in this dataset were Purina 5002, National Toxicology Program 
(NTP) 2000, and Provimi Kliba (PK) 3893.BMC Genomics 2008, 9:285 http://www.biomedcentral.com/1471-2164/9/285
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sected across arrays by probe ID. A subset of probes was
identified for which there was replicate evidence of high
variance (ranked by variance in the top 5% of expressed
targets either across tissue-array sets or for multiple probe
sets per array) or relevance to toxicogenomics (provision-
ally defined as inclusion on the Affymetrix GeneChip Rat
ToxFX 1.0 array). Using these criteria, probe sets were
identified for 373 targets that exhibited reproducible high
baseline variance in liver (n = 103), kidney (n = 121), or
both tissues (n = 149) (Additional file 6).
Gene pathways and functions most closely associated
with high baseline variance were identified using annota-
tion classification programs in the Database for Annota-
Canonical variable plots of control liver data Figure 2
Canonical variable plots of control liver data. Each panel shows the first two canonical variables, which represent the 
maximum achievable separation for each factor (in rows) and array type (column), computed from the first ten principal com-
ponents. Each point in the plot represents an individual sample. The marker color along with text indicates the factor level for 
the sample and the shape indicates the site where the data were generated. Coded study is indicated by site number followed 
by a letter indicating study within a site.
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tion, Visualization and Integrated Discovery [11]. Genes
highly variant in control liver and kidney samples were
enriched and uniquely present in the KEGG pathways
(EASE score < 0.05) for "antigen processing and presenta-
tion" (major histocompatibility complex genes), "andro-
gen and estrogen metabolism" (Hsd11b1, Hsd11b2,
Hsd17b3, Srd5a1, Ugt2b4), "maturity onset diabetes of the
young" (Foxa2, Foxa3, Gck, Onecut1), "metabolism of
xenobiotics by cytochrome P450" (Adh1, Adh4, Cyp2c40,
Cyp3a13, Cyp3a18, Cyp4a14, Ephx2), "glycine, serine, and
threonine metabolism" (Agxt2, Alas2, Chka, Dao1, Phadh,
Sds), and "biosynthesis of steroids" (Hmgcr, Idi1, Ngo1,
Sqle). Altogether, these six pathways include 43 of the
high variance genes (see Additional file 6).
Functional annotation clustering analyses using gene
ontology (GO) terms was performed to identify enriched
molecular functions and biological processes among the
remaining high variance genes. High variance genes (53
total) were enriched in four molecular function clusters
associated with (1) monooxygenase or other heme bind-
ing activity (Cyp2b2, Cyp2d26, Cyp2d9, Cyp2d10, Cyp4b1,
Cyp7a1, Cyp8b1, Cyp17a1, Hbb), (2) cytokine, growth fac-
tor, or other receptor binding activity, (3) carbohydrate
binding (Apcs, Lpl, TSP-2), and (4) transporter activity.
High variance genes (120 total) were also enriched in
three clusters of biological processes associated with the
molecular functions of (1) lipid metabolism, (2) defense
response (C3, Ctgf, Hamp, Itga1, Lbp, Spp1, Vwf), and (3)
transport (Acadsb, Akr1c6, Apoe, Cd36, Cyb5, Cyp17a1,
Cyp7a1, Cyp8b1, Egf, Egfr, Fasn, G6pc, Hspb1, Igf1, Pck1,
Pik3r1, Ppp1r3c, Ptgds, Sc4mol, Slc7a7, Srebf1, Tgfb2).
Enriched GO terms and other annotations are listed in
Additional file 6 for the high variance genes.
Expressed genes with low inherent variability are of inter-
est in toxicogenomics data analyses for data normaliza-
tion or, if significantly changed in response to exposure or
damage, as potentially reliable and specific biomarkers.
Probe targets with multiple instances of low overall vari-
ance in liver, kidney, or in both tissues were identified
across tissue-array sets. A combined non-redundant list of
163 genes with the lowest variance in control animals was
compiled for functional annotation analysis (Additional
file 7). Interestingly, this list contains 8 genes expressed in
both liver and kidney (Cyp2d26, Tf, C3, F2, ApoE, Spp2,
Rbp4, Rn.107069) that were highly variant in control kid-
ney, but among the least variant in control liver samples.
The low variance gene list was enriched (enrichment
scores > 1.5) for genes annotated with the GO cellular
component terms of mitochondrion or other organelle
membrane and for biological process clusters primarily
associated with transport or defense response. Many of
these genes identified with low overall variance are
involved in housekeeping functions often associated with
controls for gene expression studies. Examples include
Actb, Gapd, Aldoa, Pgam1, and Rps29 which are commonly
used as control genes in mammalian expression studies
[12].
Gender-selective genes in liver and kidney
To determine the dataset's utility for suggesting genes
associated with different experimental factors, we identi-
fied genes that were differentially expressed between
males and females (gender-selective genes) using EPIG, a
profile-based analysis method for Extracting microarray
gene expression Patterns and Identifying co-expressed
Genes [13]. This analysis involved transcript profiles from
14 studies carried out at 5 institutions and included data-
sets from 76 male and 58 female rat livers and 30 male
and 28 female rat kidneys (see Additional file 8). A total
of 854 or 863 genes exhibited significant differences in
expression levels between the genders in one or more
institutions in liver or kidney, respectively (see Additional
file 9). About 30% of these genes exhibited significant dif-
ferences across more than one institution (Figure 3A, left
and middle panels). Overall, 265 gender-selective genes
in liver and 305 genes in kidney showed excellent con-
cordance between institutions in terms of gender-selective
expression as well as magnitude of the difference between
genders. While 76 genes consistently exhibited similar
gender-selective behavior in both liver and kidney (Figure
3A, right panel), 22 genes showed reverse patterns of gen-
der-selective expression between liver and kidney. For
example, Ces3 was predominantly expressed in males in
liver and in females in kidney, while Prlr exhibited the
reverse behavior.
Table 3: Confounding relationships for selected factors in liver
RAE230A RAE230 2.0 RGU34A
Gender None n/a – all males None
Diet OrganSection + Fixation OrganSection + DoseDuration/Strain/SacMethod/
Vehicle
None
Strain OrganSection + Fixation SacMethod + DoseDuration/RNAAmount/Age/
Fasted/SacMethod/Diet/Vehicle/OrganSection
Diet + DoseDuration/Route/Age/OrganSection
Fasted OrganSection or Diet + Strain DoseDuration/Strain/SacMethod/Diet/Vehicle/
OrganSection
Diet + RNAAmount + Scanner/Fixation/
SacMethod/Vehicle/OrganSectionBMC Genomics 2008, 9:285 http://www.biomedcentral.com/1471-2164/9/285
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Genes that exhibited gender-selective expression in liver
or kidney were divided into 8 different groups based on
expression behavior (Figure 3B). Genes were identified
that were male-predominant (group 1) or female-pre-
dominant (group 2) in both liver and kidney, male-pre-
dominant in liver only (group 3) or kidney only (group
5), female-predominant in liver only (group 4) or kidney
only (group 6), male-predominant in liver but female-
predominant in kidney (group 7) or vice versa (group 8).
The relative expression levels of 4 to 5 genes in each group
were examined by RT-PCR in liver and kidney from con-
trol male and female rats from an independent study
using the F344/N strain (Figure 3B). Although the EPIG
analysis was performed using data from Wistar and
Sprague-Dawley rats and the RT-PCR results were gener-
ated in F344/N rats, there was generally good agreement
between the microarray and RT-PCR results, confirming
the robustness of the methods used to identify gender-
selective genes (Additional file 10).
Heat map visualizations of gender-selective genes in liver and kidney Figure 3
Heat map visualizations of gender-selective genes in liver and kidney. The color scale indicates the ratio of expres-
sion in males relative to females in the visualizations created using default settings in TreeView [32]. Red indicates higher aver-
age expression in males, green indicates higher expression in females, black indicates no significant difference between males 
and females, and gray indicates that no data was available due to the smaller genome coverage by the RGU34A arrays used by 
institutions 1 and 3 (numbers above columns indicate the institution that contributed the data). All other institutions used 
RAE230A or RAE230 2.0 arrays. (A) The left panel shows liver selective genes with a ratio range of 200 to -190, the middle 
panel shows kidney selective genes with a ratio range of 113 to -89, and the right panel shows gender-predominant genes that 
have the same or opposite direction of expression in liver and kidney over a ratio range of 81 to -190. Only those genes that 
were altered in at least two-thirds of sites for kidney, at least half of the sites for liver, or three-quarters or more of the sites 
in cross-tissue comparisons are shown. (B) Verification of identified classes of gender-selective genes. Genes that exhibited sig-
nificantly altered expression between males and females in liver or kidney were divided into 8 different groups based on 
expression behavior as indicated on the right side of the panel. Groups 1, 2, 7 and 8 exhibited gender-selective expression in 
both liver and kidney. Groups 3 and 4 exhibited gender-selective expression predominantly in liver and groups 5 and 6 exhib-
ited gender-selective expression predominantly in kidney. The expression of four to five genes from each of the groups was 
examined by RT-PCR (column C) in liver and kidney from control male and female F344 rats from an independent study. The 
relative ratios span a range from 300 to -267.
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The gender-selective genes fell into a number of func-
tional categories including those involved in "xenobiotic
metabolism" and "response to xenobiotic stimulus" (see
Additional file 11). Many of the genes in this category are
classic sexually dimorphic genes that have been previ-
ously characterized, including members of the CYP2A,
CYP2C, and CYP3A families [14]. Liver and kidney gen-
der-selective genes also included those involved in "cellu-
lar lipid metabolism", "lipid metabolism" and "fatty acid
metabolism," a number of which were identified in two
microarray studies of gene expression in the livers of male
and female rats [15-17]. Gender-selective genes in kidney
also included those involved in metabolism and transport
of other metabolites including "aromatic compound
metabolism," "carboxylic acid metabolism," and "organic
acid metabolism." The 12 named genes that exhibited
opposite regulation in liver and kidney included those
involved in estrogen metabolism (Hsd17b2), xenobiotic
metabolism (Sult1c1), lipid metabolism (Acox2,  Crot,
Pld1, Dgat2), transcriptional regulation (Cited2), and sig-
naling (Prlr, Prom1).
The gender-selective genes identified in liver were evalu-
ated for common regulatory elements in their promoters.
Three classes of transcription factor binding sites were
identified. Many of the genes contained STAT1, STAT3,
STAT5, and STAT6 sites. STAT1, STAT3, and STAT5 are
activated by growth hormone (GH) and STAT5b plays a
major role in determining gender-selective gene expres-
sion through GH-janus kinase pathways [14]. Other sites
included those recognized by the LXR-RXR, FXR-RXR, or
VDR-RXR nuclear receptor heterodimers that respond to
oxysterols, bile acids, and vitamin D, respectively. The
gender-selective genes also had a significant number of
sites recognized by CCAAT displacement protein family
members including Cut and Cux which are homeodo-
main-containing proteins that repress the transcriptional
activities of HNF-1α, C/EBPα and Rb/p107 and have not
been previously associated with gender-selective gene
expression.
Genes changed by fasting in liver and kidney
The control animal dataset was also used to identify genes
that were regulated by fasting. Although not specified,
fasting was likely to have been ~12 to 18 hr in duration,
which is typical for studies examining the effects of fasting
on organ function. The transcript profiles from a total of
11 studies carried out at 5 institutions were used to iden-
tify genes altered by fasting (Additional file 8). This data-
set included 115 .cel files for liver samples from 85 males
and 30 females from three strains of rats, with 61 animals
fed ad libitum (AL) and 54 animals fasted. Genes associ-
ated with fasting were identified by EPIG and t-test as
described in the Methods. There were a total of 190 or 311
genes that were significantly different using EPIG or t-test,
respectively, with 95% concordance between the two
methods (Additional file 12). Two-dimensional clustering
was used to determine the similarity of the gene expres-
sion profiles from the different animals (Figure 4).
Although most of the animals clustered into two distinct
clades for ad libitum fed and fasted, there were a number
of AL animals that routinely clustered with the fasted ani-
mals. These animals included those from institution 11
(studies A and B) and institution 2 (studies D and E). An
examination of the expression profiles from these animals
indicated that a number of the fasting responsive genes
were altered, although, in most cases, not to the extent
observed in the fasted animals. Thus, it is possible that
these animals were subjected to fasting conditions for
short duration either intentionally or because of housing
conditions.
Functional categorization showed that fasting altered the
expression of the same categories of genes that had previ-
ously been identified in mouse liver [18] and that are
dominated by genes involved in lipid utilization (Addi-
tional file 13). It should be noted that no global analysis
of fasting-responsive genes in rat liver has been published.
However, the impact of fasting on the interpretation of
toxicogenomics studies has been discussed [19,20].
Genes differentially regulated by gender or fasting state
also tended to have high baseline variability. Approxi-
mately 34% of the gender and fasting genes are included
in the 500 RAE230A probe sets that have the highest base-
line variability (3% of the total array content) and all gen-
der or fasting genes are included among the top ~31%
most variant probe sets (Additional file 14). This indicates
that genes that respond to fasting, presumably through
nutritional cues, and those gender-predominant genes
that are under control of growth hormone substantially
contribute to variability in a liver gene expression profile.
Discussion
Through the consortial efforts of participants in the HESI
Committee on Genomics, a unique resource has been
assembled that connects gene expression levels in the liver
and kidney of rats from the control arms of numerous,
diverse toxicogenomics studies to specific study meta-
data. This dataset and the complete results of variability
analyses described in this manuscript are available for fur-
ther data mining in the CEBS-BID and EBI ArrayExpress
public databases. One outcome from this project is the
identification of key descriptors that should be included
in the minimal information about a toxicogenomics study
needed for interpretation of results by an independent
source. Among the key descriptors are those that are
prominent sources of variability in baseline gene expres-
sion.BMC Genomics 2008, 9:285 http://www.biomedcentral.com/1471-2164/9/285
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Two dimensional hierarchical clustering of genes that exhibited altered expression in liver samples from ad libitum (AL) fed or  fasted rats Figure 4
Two dimensional hierarchical clustering of genes that exhibited altered expression in liver samples from ad 
libitum (AL) fed or fasted rats. Genes that were significantly changed by overnight fasting were identified using either (A) 
EPIG (n = 190 genes) or (B) t-test (n = 311 genes) analysis of data from 115 cel files and 5 sites. Gene expression levels were 
normalized to the average AL fed value and color-coded on a fold change scale of 6.4 to -9.5 (red to green), using default con-
trast settings in TreeView [32].
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Multivariate variability analysis of the baseline expression
dataset revealed gender, fasting, and organ section as
some of the most prominent factors associated with over-
all transcriptional changes, although most of the seven-
teen factors included in the multivariate analyses
appeared to be a significant source of variability in at least
one of the six tissue-array datasets. Fasting tended to be a
stronger source of variability in liver than kidney, while
organ section was a more prominent source of variation in
kidney than liver. In agreement with a recent study that
examined gene expression profiles in kidney slices [21],
we observed that the cortex was more similar to whole
kidney than the medulla.
The observational nature of this study severely hinders
causal inference, but the results can provide at least some
positive associations of particular factors of interest. For
example, unambiguous gender and organ section differ-
ences were discernable. On the other hand, while it is
hypothesized that certain variables within a study factor
field may contribute disproportionally to the observed
variance (e.g., the use of oil as a vehicle or a diet lower in
protein or phytoestrogens), many of these could not be
confirmed with the current dataset because of confound-
ing with other factors. Hypotheses generated from these
data could be tested by experiments specifically designed
to test the variability due to specific factors of interest.
Many of the genes identified as having high baseline vari-
ability have relevance to toxicology. This list includes
many genes involved in the absorption, distribution,
metabolism, and excretion of drugs (e.g., members of the
ABC and SLC transporter superfamilies, phase I and II
enzymes) and is also enriched for genes involved in
defense response. Similar results were observed in a recent
study of variability in the human liver transcriptome [22].
Among 75 diverse individuals, the most variable hepatic
genes were involved in drug and intermediary metabo-
lism, inflammation, and cell cycle control. One contribut-
ing factor to high baseline variability may be increased
sensitivity in transcriptional response to environmental
cues. Therefore, it follows that some of most variable
genes in control animals could also be significantly
changed by exposure to drugs or chemicals. As an exam-
ple, we compared the list of gene transcripts with high
baseline variance (in Additional file 6) to significant gene
changes observed across laboratories in collaborative
research studies conducted by the HESI Committee on
Genomics [23]. About 20 percent of the genes associated
with renal injury by cisplatin across multiple platforms
(Col1a1, Egf, G6pc, Igfbp3, Lcn2, Rpb4, Spp1, Ugt2b) [24] or
significantly regulated in liver by the hepatotoxin clofi-
brate (Cyp17a1, Hspa1a, Cpt1a, Egr1) [25] were also iden-
tified to have high baseline variance in this study.
However, genes with high baseline variability may be
identified as statistically different between treatment
groups of small size without actually being changed by
treatment.
To illustrate the utility of the multi-site control animal
dataset for identifying gene changes associated with spe-
cific study factors, we focused on two factors, gender and
fasting, that had the greatest contribution to variance in
the largest number of tissue-array sets (see Table 2).
Although strain and organ section also ranked high and
are important variables in toxicogenomics studies, an
analysis of gene changes associated with these factors was
not included in this manuscript because of certain con-
straints with the available data sets. For example, fasting
was confounded by strain in the Liver-RAE230 2.0 set and
by strain and gender in the Liver-RAE230A set. We did not
consider liver section to be a well standardized term based
on the responses received. Although kidney section was
clearly associated with significant differences in gene
expression levels, only one site contributed data for differ-
ent kidney sections. Investigators are encouraged to use
the control animal dataset for exploratory analysis of
genes changes associated with strain or tissue section.
The dataset showed utility for identifying genes that
exhibit differential expression in males and females as
well as genes that are altered by fasting. The large number
of rats in the analysis (192) provided a unique statistical
power to identify novel genes that exhibit gender-selective
gene expression and can be used for further elucidation of
regulatory control elements, some of which may depend
on tissue context. Identification of differences in gene
expression between genders in tissues that are important
in the response to and metabolism of pharmaceuticals or
environmentally relevant chemicals will be useful for
understanding the functional basis of gender differences
in the pharmacology and toxicology of these compounds.
In planning microarray expression experiments, this
paper highlights a number of concerns that an investiga-
tor should consider in defining a new experiment or in
comparisons with reported results. Gender, strain, diet,
and tissue section within an organ can all play a role in
defining baseline gene expression. In the case where
known experimental factors are controlled, there are
genes that show inherent variability. Future experiments
could be designed to uncover the factors that can account
for this variability. Alternatively, variability in expression
may be due to other biological factors that were not iden-
tified here. In designing an experiment with few biological
replicates, one of these highly variable genes may ran-
domly partition into an experimental group leading to an
attribution of the change in gene expression to an experi-
mental factor. The online and supplementary materials
can be used to identify genes which are significantlyBMC Genomics 2008, 9:285 http://www.biomedcentral.com/1471-2164/9/285
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altered by external factors as well as genes which have
high inherent variability.
Methods
Data access
The raw data (.cel files), RMA normalized data, MAS 5.0
processed data, and report files are available at the EBI
ArrayExpress database [10] under accession number E-
TOXM-39. In CEBS-BID [9], the data are provided in a sin-
gle investigation ("HESI Baseline", Accession 008-00003-
0001-000-2), containing 18 studies, each corresponding
to a contributing laboratory. Within each laboratory, indi-
vidual in-life studies are represented by groups.
Array outlier analysis and data normalization
Several steps were taken to ensure data consistency across
datasets contributed by different institutions. First, arrays
(n = 34) scanned using high PMT settings were ignored for
better inter-array comparability. Second, duplicated .cel
files (n = 2) with identical data contents but different
experimental annotation were identified by pair-wise
comparison and removed. Third, for the remaining 500
scans, Affymetrix .rpt files, generated from processing .cel
files using MAS 5.0 software [26] with total chip intensi-
ties scaled to an average intensity of 250 and with manu-
facturer-defined default parameters, were analyzed to
further identify quality outliers. The quality metrics ana-
lyzed from .rpt files include percentage of present calls,
scaling factor, average and maximum background, as well
as 3' to 5' signal ratios for the Affymetrix control tran-
scripts. Scans (n = 17) exceeding arbitrary cutoffs for scal-
ing factor (>10), average background (> 120), or
maximum background (> 130) were excluded from fur-
ther analysis. Because measures of different quality met-
rics correlate with each other, the excluded outliers also
had significantly lower percentage present calls and
higher 3' to 5' signal ratios for glyceraldehyde-3-phos-
phate dehydrogenase and β-actin, as compared to the
retained arrays.
The 483 arrays remaining after outlier exclusion were
processed using RMA. For each of the three separate RMA
runs corresponding to the three different array types, the
individual perfect match (PM) probe values were back-
ground-corrected and quantile normalized before com-
puting the expression values, as described by Irizarry et al.
[27]. Besides using RMA as our default normalization
method, we also assessed the impact of normalization on
data analysis by comparing RMA results with results
derived from MAS 5.0 and dChip [28]. Only marginal dif-
ference was observed in outcomes among the three differ-
ent normalization methods, including correlation
coefficients of the expression values and agreement of lists
of significant genes identified using statistical tests.
Variability analysis
Hotelling-Lawley (HL) statistics [29] were computed indi-
vidually for each of the 15 factors for which there is com-
plete (no missing) data and for two factors with partially
filled values (Organ Section, which has 5 missing values
in the RGU34A Liver subset and Scanner which contains
104 (out of a total of 483) values that were coded as 0
(unknown)). Studies that were submitted from different
sites within the same parent institution were coded as sep-
arate laboratories. Sites 12 and 15 represent different
research centers within one company, as do sites 3 and 5.
HL was computed using the first ten principal compo-
nents as a multivariate response, and then standardized to
be between 0 and 1 by dividing by HL statistic for the max-
imal model consisting of all distinct factor combinations.
A threshold for significance of the HL statistics was set
empirically at 0.35.
To provide a competitive partitioning of sources of varia-
bility, a variance components (VC) model was fitted sep-
arately to each of the first ten principal components.
Considering a particular principal component score vec-
tor to be a univariate response, the 17 aforementioned fac-
tors were modeled together as Gaussian random effects on
that response and a variance component was estimated
for each, using restricted maximum likelihood [30]. The
model is invariant to ordering of the effects, except when
there is complete confounding. Because of the possibility
of confounding for certain data subsets, the effects for Lab
and Study(Lab) were always specified last in the model in
order to give the other, known, confounded sources of
variability priority in explaining variability. The ten REML
variance component estimates for each factor were aver-
aged, using the corresponding eigenvalues as weights. A
weighted-average REML estimate of residual (unex-
plained) variability was also computed. The final set of
weighted-average estimates were divided by their sum to
yield a proportion-of-total-variability estimate for each
factor and the residual variance. The residual error was the
cutoff for significance for a VC statistic.
The first ten principal components for each of the six data
subsets were also used as predictors in a classical linear
discriminant analysis (LDA) [29]. LDA was conducted
separately on the following factors: gender, diet, strain,
and fasting, as well as study(lab) as a reference. Canonical
scores from this analysis are based on the eigen-decompo-
sition of a function of the between and within cross-prod-
ucts matrices of the corresponding multivariate analysis of
variance. The canonical scores represent directions of
maximal separability for the factor levels.
The same four factors were also predicted using other fac-
tors in order to discern confounding patterns. A partition
tree (recursive partitioning) algorithm was used here. In aBMC Genomics 2008, 9:285 http://www.biomedcentral.com/1471-2164/9/285
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few cases (e.g. gender), no obvious confounding was
apparent, which provides support in these cases that this
factor was in fact the true source of variability. In other
cases, many factors were completely confounded, making
it difficult to pinpoint true sources.
The preceding variability analyses were performed using
MatLab and JMP Genomics software.
Real-time RT-PCR analysis
The relative levels of expression of selected genes were
quantified using real-time RT-PCR analysis. Tissues were
derived from an independent study carried out at the US
EPA using 8–9 week old male and female F344/N rats.
Only control rats were used to validate microarray results.
Liver and kidney RNA was isolated using a modified gua-
nidium isothiocyanate method (TRIzol®, Invitrogen,
Carlsbad, CA) and was further purified using silica mem-
brane spin columns (RNeasy®, Qiagen, Valencia, CA).
RNA quantification was determined using a Nanodrop
spectrophotometer and RNA integrity was assessed by the
RNA 6000 LabChip® Kit using a 2100 Bioanalyzer (Agilent
Technologies, Palo Alto, CA). Total RNA was reverse tran-
scribed with MuLV reverse transcriptase and oligo-dT
primers. The forward and reverse primers for selected
genes (see Additional file 15) were designed using Primer
Express software, v2.0 (Applied Biosystems, Foster City,
CA). The Power SYBR® Green PCR Master Mix (Applied
Biosystems, Foster City, CA) was used for real-time PCR
analysis. Reactions were run in duplicates and repeated
twice. The Ct values of the genes were first normalized to
β-actin and 18s rRNA levels in the same sample, and then
the relative differences between control and treatment
groups were calculated and expressed as relative increases,
setting the control as 100%. Means and S.E. (n = 3) for RT-
PCR data were calculated by Student's t test. The level of
significance was set at P ≤ 0.05.
EPIG analysis
EPIG extracts a set of patterns representing co-expressed
genes without pre-defined seeding of the patterns [13].
The method uses gene expression profile Pearson correla-
tion measures, magnitude of change, and signal-to-noise
evaluations to categorize genes into patterns that repre-
sent co-expressed genes. A 2-dimensional matrix of micro-
array gene expression data (log2  pixel intensity ratio
values) with each row representing a gene expression pro-
file and each column representing an array is used for
analysis. A gene expression profile can be made between
and within groups. The arrays in within-groups have a fac-
tor in common, e.g. biological replicates. The arrays in
between-groups possess different factors, e.g., fasting or
gender. We denote each data of log2 ratio as gij in a gene
expression profile, where i refers to a between-group index
from 1 to m, j is the within-group index from 1 to ni, m is
the number of between-groups and ni is the number of
arrays in ith between-group.
Briefly, using all pair-wise correlations, any candidate pro-
file whose local cluster size is less than a predefined size
Mt or correlation is higher (> Rt) but has a lower relative
local cluster size M is removed from pattern construction
consideration. EPIG then creates representative profiles
for the corresponding local clusters. Lastly, candidate pro-
files with a signal-to-noise ratio < 3 (the number of time
the signal is above the noise) or its magnitude of expres-
sion S < 0.5 is removed from consideration in the pattern
building process. Subsequently, EPIG categorizes each of
these genes to one of the patterns, with which it has the
highest correlation value of the gene profile. A gene not
assigned to any extracted patterns is considered an
"orphan" if its highest Pearson correlation r-value is lower
that a given threshold Rc. Typically Rc is set to a value
which corresponds to a correlation p-value of 10-4 to
assure the significance of the co-expression. For this anal-
ysis, Mt was set to 6 and Rt set to 0.8.
Genes were selected with the following cut-offs: Log2 ratio
≥ 0.5 (or ≤ -0.5) and p-value ≤ 0.001. Biological analysis
was performed using the Gene Ontology function of
GeneGo with the help of KEGG [31]. In the figures and
additional files for genes selective for gender or fasting,
fold change is reported as the negative reciprocal value if
less than one. Analysis of regulatory elements within the
promoters of gender-selective genes was performed using
Genomatix software (Genomatix Software GmbH,
Munich, GER).
Probe set variability analysis
A baseline variance was calculated for each probe set
within each tissue-array set based on the maximal model,
in which each unique combination of factors was
encoded as a distinct group. These values are available
through CEBS-BID and EBI. Variance within each group is
interpreted as baseline variability and is not due to any of
the study factors for which information was collected.
In order to define whether a probe set is detectably
expressed, the signal strength of perfect match (PM)
probes was compared to the signal strength of mismatch
(MM) probes in a two way test for equal intensity using
the log of the baseline adjusted intensities. Probe sets with
PM ≠ MM signals (P < 0.05) in ≥ 80% of samples per tis-
sue-array set were defined as expressed in a given tissue in
this study. The fraction of probe sets with expressed sig-
nals ranged from 30% (in the liver-RGU34A set) to 50%
(for the kidney-RAE230A set) of the total number of
probe sets on each array type. Probe sets were matched
between the RGU34 and RAE230 series using "Best
Match" sequence mapping files available from the manu-BMC Genomics 2008, 9:285 http://www.biomedcentral.com/1471-2164/9/285
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facturer or by UniGene identifier (July 2006 update). To
identify genes with multiple instances of low overall vari-
ance, the 200 least variant probe sets in each tissue-array
set were intersected by probe identifier.
Overrepresentation of biological themes among most and
least variant genes was performed in DAVID using func-
tional annotation clustering analysis [11]. The 8630 probe
sets expressed in liver or kidney on the RAE230A array
were used as the population background for enrichment
analysis. Enrichment analysis was performed for annota-
tion clustering by KEGG pathway, Gene Ontology (GO)
Molecular Function Levels 2 and 3, GO Cellular Compo-
nent Levels 3 and 4, or GO Biological Process Levels 3 and
4. The threshold for labeling an annotation cluster as
enriched was an enrichment score > 1.5.
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Additional material
Additional file 1
Distribution of responses for 26 study factors that annotate the 483 
control animal .cel files analyzed in this manuscript. This file contains 
a tabulation of the responses reported on the survey forms that were 
received for each submitted Affymetrix .cel file for a control animal sample 
from toxicogenomics studies conducted at each institution. The fractional 
count per response is based on the total number of responses received, 
which were not complete for every study factor. Some responses were har-
monized or binned in order to facilitate analyses of study factor variability.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-9-285-S1.pdf]
Additional file 2
Principal component analyses of tissue-array sets. Principal compo-
nents were computed for normalized intensities from samples of given tis-
sue-array combinations. Plots of the first two principal components are 
shown with the axis indicating the amount of variance in each component 
as a percentage of the total.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-9-285-S2.ppt]
Additional file 3
Tabular display of study factor combinations alongside the HL and VC 
statistics for each tissue-array set of control data. Hotelling-Lawley 
(HL) and Variance Components (VC) scores were computed for each of 
17 study factors in each six tissue-array set. Scores in bold were above the 
threshold for significance. A threshold for significance of the HL statistics 
was set empirically at 0.35. The residual error was the cutoff for signifi-
cance for a VC statistic.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-9-285-S3.xls]
Additional file 4
Canonical variable plots of control kidney data. Each panel shows the 
first two canonical variables, which represent the maximum achievable 
separation for each factor (in rows) and array type (column). Each point 
in the plot represents an individual sample. The marker color along with 
text indicates the factor level for the sample and the shape indicates the 
site where the data were generated.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-9-285-S4.ppt]
Additional file 5
Confounding relationships for selected factors in kidney. This table 
shows factors observed to be confounded with those analyzed in Figure 2. 
The confounding relationships were determined by fitting a partition tree 
model to each factor (gender, diet, strain, or fasted), using the other 16 
factors as predictors.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-9-285-S5.doc]BMC Genomics 2008, 9:285 http://www.biomedcentral.com/1471-2164/9/285
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Additional file 6
List of Affymetrix probe sets associated with high variance in control 
rat liver and/or kidney. This list contains 373 genes with replicate evi-
dence of high baseline variance among the six tissue-array sets. Baseline 
variance was calculated for each probe set (within each tissue-array set) 
based on the maximal model, in which each unique combination of factors 
was encoded as a distinct group. Using these variance measurements, 
probe sets that were ranked in the top 2% in baseline variance among 
expressed targets were intersected across tissue-array sets by probe identi-
fier. The intersected list was then filtered for probe sets that were among 
the top 5% most variant on at least a second tissue-array set, or that were 
relevant to toxicogenomics (defined here as inclusion on the Affymetrix 
GeneChip Rat ToxFX 1.0 array). Column A: Probe set identifier on 
Affymetrix RAE230 and ToxFX arrays, Column B: Probe set identifier on 
Affymetrix RGU34 arrays, intersected by Affymetrix Best Match sequence 
mapping file or UniGene ID (grey background), Columns C-E: UniGene 
identifier, Gene Name, and Gene Symbol, Column F: Tissue where high 
variance observed; Liver (L), kidney (K), or both liver and kidney (B), 
Column G: Inclusion on the Affymetrix ToxFX 1.0 array: Yes (Y) or No 
(N), Column H: Functional annotation associated with the probe set, 
identified using the following sources of curation in DAVID [11], KEGG: 
Kyoto Encyclopedia of Genes and Genomes pathway; BP: Gene Ontology 
Biological Process; MF: Gene Ontology Molecular Function; CC: Gene 
Ontology Cellular Compartment; COG: Clusters of Orthologous Groups 
of Proteins; SP: Swiss Prot knowledgebase ; IP, Interpro database.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-9-285-S6.xls]
Additional file 7
List of Affymetrix probe sets associated with low variance in control 
rat liver and/or kidney. This list contains 163 genes with replicate evi-
dence of low baseline variance among the six tissue-array sets. Baseline 
variance was calculated for each probe set (within each tissue-array set) 
based on the maximal model, in which each unique combination of factors 
was encoded as a distinct group. Using these variance measurements, 200 
probe sets with the lowest baseline variance among expressed targets were 
intersected across tissue-array sets by probe identifier. The intersected list 
was then filtered for probe sets that were among the 200 least variant on 
at least a second tissue-array set. Column A: Probe set identifier on 
Affymetrix RAE230 and ToxFX arrays, Column B: Probe set identifier on 
Affymetrix RGU34 arrays, intersected by Affymetrix Best Match sequence 
mapping file or UniGene ID (grey background), Columns C-E: UniGene 
identifier, Gene Name, and Gene Symbol, Column F: Tissue where high 
variance observed; Liver (L), kidney (K), or both liver and kidney (B), 
Column G: Functional annotation associated with the probe set, identified 
using DAVID [11].
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-9-285-S7.xls]
Additional file 8
Sources of data used to identify gender-specific and fasting-related 
genes. The institution number, study code, and key descriptors for the data 
sets used in the EPIG analyses of genes associated with gender-selective 
expression or with expression changed by fasting state are listed. Study 
codes were assigned to distinguish independent studies submitted from the 
same institution.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-9-285-S8.doc]
Additional file 9
List of probe sets identified as gender-selective using EPIG. This file 
contains lists of gender-selective probe sets on Affymetrix RAE230 series 
and RGU34A arrays and the average fold-change difference within each 
tissue array set used in the analysis (male to female expression ratio). Fold 
changes less than one are reported as negative reciprocal fold changes. A 
list of probe sets with correlative and anti-correlative gender-selective 
expression between liver and kidney is also provided.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-9-285-S9.xls]
Additional file 10
Results of real-time RT-PCR analysis of gender-difference genes in liv-
ers and kidneys of F344/N rats. Gender-selective expression of a subset 
of genes identified by EPIG analysis of the control animal dataset was ver-
ified in an independent study using RT-PCR. Each RT-PCR experiment 
was run twice with similar results. The expression levels in each animal 
were evaluated in duplicate, with 3 animals per group.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-9-285-S10.doc]
Additional file 11
Gene ontology analysis of gender-specific genes in the rat liver and 
kidney. Results of analysis performed using the Gene Ontology function 
of GeneGo with the help of KEGG [31]. The max(-log(p-value)) is the 
result of a hypergeometric test using GeneGo. The higher the score, the 
greater the significance of the network. Network objects refers to the 
number of objects identified divided by the total number of objects in the 
network in the GeneGo database.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-9-285-S11.doc]
Additional file 12
List of probe sets identified as altered by fasting using EPIG or a t-test. 
This file contains lists of Affymetrix RAE230 series probe sets that were 
significantly different in expression between fasted and ad libitum fed 
rats in the control animal dataset. For each probe set, the gene symbol, 
name, test statistic, and average fold change difference between fasted vs. 
non-fasted rats are provided. Fold changes less than one are reported as 
negative reciprocal fold changes.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-9-285-S12.xls]
Additional file 13
Gene ontology analysis of fasting-associated genes in the rat liver 
identified using a t-test or EPIG. Results of analysis performed using the 
Gene Ontology function of GeneGo with the help of KEGG [31] is the 
result of a hypergeometric test using GeneGo. The higher the score, the 
greater the significance of the network. Network objects refers to the 
number of objects identified divided by the total number of objects in the 
network in the GeneGo database.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2164-9-285-S13.doc]BMC Genomics 2008, 9:285 http://www.biomedcentral.com/1471-2164/9/285
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